Lindner, S M. (March 6, 2017). Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis. Circulation, 135, . doi:10.1161/CIRCULATIONAHA.116.024666

"Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin : A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis / Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators" Circulation .

Lindner, Samuel M. "Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis." Circulation 135 (March 6, 2017).